Le mode conseil est activé Arrêter
Pour la navigation rapide entre les blocs

Organisation: Ligand
LEI 5493008K7TB0IKP37H79

Nom de l'organisation
Ligand Pharmaceuticals, Inc
Nom du pays
États-Unis
Pays d'enregistrement
États-Unis
Secteur économique
Production de médicaments et biotechnologies
Dette obligataire
-

explorer la base de données la plus complète

800 000

obligations globalement

Plus de 400

sources de prix

80 000

actions

9 000

ETF

suivre votre portefeuille de la manière la plus efficace
screener d'obligations
liste de surveillance
Excel ADD-IN
Obtenir l'accès

Dernières données pour

Cotations

Requête envoyé
Accès refusé
Envoyer la requête
Les cotations fournis par les fournisseurs d’information sont de nature indicative

Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company’s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer’s VFEND IV and Baxter International’s Nexterone and is being used in a number of clinical-stage partner programs. The therapies in its portfolio in development address the unmet medical needs of patients for a spectrum of diseases, including hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. It’s wholly owned subsidiaries include Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., Pharmacopeia, LLC, Neurogen Corporation, CyDex Pharmaceuticals, Inc. and Metabasis Therapeutics. 

Récompenses

Actualités

27/02/2024 Ligand: Results Of Operations And Financial Condition, Financial Statements And Exhibits
05/01/2024 Ligand: Other Items
29/11/2023 Ligand: Enter Into A Material Definitive Agreement
09/11/2023 Ligand: Results Of Operations And Financial Condition, Financial Statements And Exhibits
18/10/2023 Ligand: Other Items
Toutes les actualités de l'organisation

Documents

Etats financiers IFRS / US GAAP

2023
I q ang
II q ang
III q ang
IV q ang
2022
I q ang
II q ang
III q ang
IV q ang
2021
I q ang
II q ang
III q ang
IV q ang
2020
I q ang
II q ang
III q ang
IV q ang
2019
I q ang
II q ang
III q ang
IV q ang
2018
I q ang
II q ang
III q ang
IV q ang
2017
I q ang
II q ang
III q ang
IV q ang
2016
I q ang
II q ang
III q ang
IV q ang
2015
I q ang
II q ang
III q ang
IV q ang
2014
IV q ang
Afficher tout Masquer
Il faut s'enregistrer
Envoyer la demande d'accès accès

Actions

Dernières émissions

Montrer tout

Dette obligataire par devise

Montrer tout Cacher

Codes

  • LEI
    5493008K7TB0IKP37H79
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0000886163
  • EIN
    77-0160744

Notations de crédit et notations d’ESG

Macroéconomie

Vous devez vous inscrire pour y accéder.